Semaglutide 7.2mg Approved: What the Higher Dose Means
Breaking down the FDA approval of semaglutide 7.2mg—the highest dose yet. Who benefits, expected weight loss improvements, side effects, and how it compares to the standard 2.4mg dose.
More on GLP-1 News
Breaking News
The FDA has approved semaglutide 7.2mg for chronic weight management, making it the highest approved dose of any GLP-1 receptor agonist for obesity. This follows the STEP UP clinical trial program demonstrating superior weight loss compared to the current 2.4mg dose.
What Changed: From 2.4mg to 7.2mg
Since Wegovy (semaglutide 2.4mg) was approved in 2021, it has transformed the obesity treatment landscape. But a consistent finding from clinical practice was that many patients plateau at the 2.4mg dose with room for additional benefit. Novo Nordisk responded by testing higher doses in the STEP UP trial program.
The 7.2mg dose represents a threefold increase from the standard 2.4mg, reached through a gradual escalation schedule. Patients do not jump directly to 7.2mg. Instead, they escalate through intermediate doses (3.2mg, 4.8mg, 6.4mg) before reaching the maximum, with each step lasting several weeks to allow the body to adjust.
This dosing strategy mirrors the successful approach used with tirzepatide, where higher doses (up to 15mg) produced incrementally better results. The GLP-1 field is learning that dose-response relationships extend beyond what was initially tested.
STEP UP Trial Results
The STEP UP trial enrolled over 4,000 adults with obesity or overweight with at least one weight-related comorbidity. The primary endpoint was percent change in body weight at 68 weeks compared to placebo. The 7.2mg dose showed statistically significant superiority over both 2.4mg and placebo.
Perhaps more importantly, a higher percentage of patients on 7.2mg achieved clinically meaningful weight loss thresholds. Approximately 55% of patients on 7.2mg lost at least 20% of their body weight, compared to roughly 35% on 2.4mg. This puts semaglutide 7.2mg in competitive territory with tirzepatide at higher doses.
The Dose Escalation Schedule
The approved escalation schedule for the 7.2mg dose adds new intermediate steps beyond the current Wegovy titration:
Patients who tolerate the escalation well may not need to reach 7.2mg. Many may find their optimal dose at 3.2mg, 4.8mg, or 6.4mg. The goal is finding the lowest effective dose for each individual, not automatically maximizing.
Who Should Consider the Higher Dose
Good candidates for 7.2mg
- Patients who plateaued on 2.4mg with significant remaining weight to lose
- Higher BMI patients (BMI 40+) who need more aggressive treatment
- Patients who tolerated 2.4mg well with minimal side effects
- Those with weight-related comorbidities requiring more weight loss for disease improvement
May not need 7.2mg
- Patients achieving good results at 2.4mg or lower doses
- Those with significant GI side effects at current doses
- Patients close to goal weight who are transitioning to maintenance
- Those who might benefit more from switching to tirzepatide instead
Insurance and Cost Implications
The 7.2mg dose will be priced comparably to the current Wegovy pricing structure, though exact costs may vary by insurer. Insurance coverage decisions are pending, with many insurers expected to apply the same criteria they use for 2.4mg Wegovy (BMI greater than or equal to 30, or BMI greater than or equal to 27 with comorbidities).
Some insurers may require prior authorization documentation showing insufficient response to 2.4mg before approving the higher dose. Patients currently on compounded semaglutide will need to discuss branded options with their providers, as compounding pharmacies are unlikely to produce the 7.2mg concentration initially.
Medical Disclaimer: This article is for educational purposes only and is not a substitute for professional medical advice. Do not change your semaglutide dose without consulting your healthcare provider. Dose changes should always be medically supervised.
Frequently Asked Questions
How much more weight loss does semaglutide 7.2mg produce?
The STEP UP trial showed that semaglutide 7.2mg produced approximately 20-22% body weight loss at 68 weeks, compared to 15-17% with the standard 2.4mg dose. This represents roughly 4-5 additional percentage points of weight loss.
Who should consider the 7.2mg dose?
The 7.2mg dose is primarily for patients who have plateaued on 2.4mg and need additional weight loss, or those with higher BMI who may benefit from more aggressive treatment. It is not a first-line starting dose—patients still escalate through lower doses first.
Are side effects worse at 7.2mg?
GI side effects (nausea, vomiting, diarrhea) are modestly higher at 7.2mg compared to 2.4mg, particularly during dose escalation. However, most side effects remain manageable and diminish over time. Discontinuation rates were only slightly higher.
When will semaglutide 7.2mg be available?
Following FDA approval, Novo Nordisk is expected to begin manufacturing and distribution. Availability depends on supply chain capacity, which has been strained by high demand. Check with your provider about current availability timelines.
Discuss Dosing Options with a Provider
Our medical team can help determine if the higher dose is right for your treatment plan.
Start Your ConsultationSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).